Catalyst Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Catalyst Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Catalyst Pharmaceuticals Inc Strategy Report
- Understand Catalyst Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Catalyst Pharmaceuticals Inc (Catalyst) develops and commercializes innovative therapies for the treatment of chronic neuromuscular and neurological diseases. The company’s products under development include Firdapse (amifampridine phosphate) and CPP-109. The company’s lead product, Firdapse (amifampridine phosphate) is a neuronal potassium channel blocker indicated for treatment of Lambert-Eaton myasthenic syndrome (LEMS), musk-myasthenia gravis, spinal muscular atrophy, downbeat nystagmus and congenital myasthenic syndromes (CMS).
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company has allocated all of its research and development resources to the advancement of Firdapse, CPP-109 (their version of vigabatrin), and previously CPP-115. As of now, the company anticipate that its future development expenses will primarily be associated with the ongoing progress of Firdapse, unless they obtain or secure licenses for new products. The company is currently investigating Firdapse under Phase III clinical trials for the treatment of lambert-eaton myasthenic syndrome (LEMS) in pediatric patients. In FY2022, the company spent US$19.8 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer